5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA

被引：0
|
作者：
Wallner, Lauren
DiBello, Julia
Li, Bonnie
Van Den Eeden, Stephen
Weinmann, Sheila
Ritzwoller, Debra
Abell, Jill
D'Agostino, Ralph, Jr.
Loo, Ronald
Aaronson, David
Richert-Boe, Kathryn
Horwitz, Ralph
Jacobsen, Steven
机构：
来源：
JOURNAL OF UROLOGY | 2016年 / 195卷 / 04期
关键词：
D O I：
10.1016/j.juro.2016.02.1937
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP04-02
引用
收藏
页码：E27 / E28
页数：2
相关论文
共 50 条
  • [1] 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia
    Wallner, Lauren P.
    DiBello, Julia R.
    Li, Bonnie H.
    Van Den Eeden, Stephen K.
    Weinmann, Sheila
    Ritzwoller, Debra P.
    Abell, Jill E.
    D'Agostino, Ralph, Jr.
    Loo, Ronald K.
    Aaronson, David S.
    Richert-Boe, Kathryn
    Horwitz, Ralph I.
    Jacobsen, Steven J.
    [J]. MAYO CLINIC PROCEEDINGS, 2016, 91 (12) : 1717 - 1726
  • [2] 5-alpha Reductase Inhibitors and Prostate Cancer Incidence and Mortality among Men with Benign Prostatic Hyperplasia
    Bhaskaran, Krishnan
    Douglas, Ian
    Smeeth, Liam
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 479 - 479
  • [3] Risk of Gynecomastia with Use of 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Nickel, J. Curtis
    Fang, Shona
    Jick, Susan S.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 531 - 532
  • [4] The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
    Ayodele, Olulade
    Cabral, Howard J.
    McManus, David
    Jick, Susan
    [J]. CLINICAL EPIDEMIOLOGY, 2021, 13 : 661 - 673
  • [5] Re: The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs)
    Ayodele, O.
    Cabral, H. J.
    McManus, D.
    Jick, S.
    [J]. JOURNAL OF UROLOGY, 2022, 207 (01): : 202 - 202
  • [6] The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
    Kim, Eric H.
    Brockman, John A.
    Andriole, Gerald L.
    [J]. ASIAN JOURNAL OF UROLOGY, 2018, 5 (01) : 28 - 32
  • [7] Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
    Hagberg, Katrina Wilcox
    Divan, Hozefa A.
    Fang, Shona C.
    Nickel, J. Curtis
    Jick, Susan S.
    [J]. CLINICAL EPIDEMIOLOGY, 2017, 9 : 83 - 91
  • [8] The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality
    Wallner, Lauren P.
    DiBello, Julia R.
    Li, Bonnie H.
    Van den Eeden, Stephen K.
    Weinmann, Sheila
    Ritzwoller, Debra P.
    Abell, Jill E.
    D'Agostino, Ralph, Jr.
    Loo, Ronald K.
    Aaronson, David S.
    Horwitz, Ralph, I
    Jacobsen, Steven J.
    [J]. UROLOGY, 2018, 119 : 70 - 78
  • [9] ASSESSING PRIMARY CARE PHYSICIANS AWARENESS OF 5-ALPHA REDUCTASE INHIBITORS FOR MEN WITH BENIGN PROSTATIC HYPERPLASIA
    Babar, M.
    Loloi, J.
    Azhar, U.
    Labagnara, K.
    Salami, A.
    Tang, K.
    Robles, J.
    Maria, P.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [10] 5α-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
    Rittmaster, Roger S.
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (02) : 389 - 402
12345